SAN FRANCISCO—The prostate cancer gene 3 (PCA3) molecular urine test is more accurate than the PSA test in predicting outcomes of repeat biopsies, new findings confirm.

Onset of statin use is associated with a significant reduction in serum PSA level, data suggest.

A study of a large multiethnic cohort found that African-American men had a higher prevalence of PSA screening than white and Latino men.

After a median of 32 months, PSA was undetectable in 12% of patients.

The likelihood of an abnormal finding is 46% lower in obese men than normal-weight men, study shows

Positive margins at the prostate base are associated with the worst outcomes.

Researchers observe positive T cell responses in men with nonmetastatic recurrence prostate cancer.

Among men who experience PSA recurrence following radical prostatectomy (RP) for prostate cancer, a PSA doubling time (PSADT) of less than nine months at the time of recurrence is associated with a significantly increased risk of death, according to a study.

ORLANDO—Men with PSA values of 1.5-4 ng/mL have a significantly elevated four-year risk of being diagnosed with prostate cancer compared with men who have PSA levels below 1.5, according to a retrospective study of 21,502 men.

Prostate cancer patients who use statins may be at lower risk of PSA recurrence after radical prostatectomy (RP) compared with those who do not use the medications, according to investigators.